Halozyme Therapeutics Income from Continuous Operations 2010-2024 | HALO
Halozyme Therapeutics income from continuous operations for the twelve months ending June 30, 2024 was $0.337B, a 44.32% increase year-over-year.
- Halozyme Therapeutics annual income from continuous operations for 2023 was $0.282B, a 39.31% increase from 2022.
- Halozyme Therapeutics annual income from continuous operations for 2022 was $0.202B, a 49.81% decline from 2021.
- Halozyme Therapeutics annual income from continuous operations for 2021 was $0.403B, a 211.97% increase from 2020.